Neon Therapeutics Inc (NASDAQ:NTGN) Short Interest Update

Neon Therapeutics Inc (NASDAQ:NTGN) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 600,600 shares, a growth of 5.4% from the June 30th total of 569,900 shares. Approximately 4.4% of the shares of the company are short sold. Based on an average trading volume of 180,700 shares, the days-to-cover ratio is presently 3.3 days.

NASDAQ NTGN traded up $0.09 on Friday, reaching $2.90. The stock had a trading volume of 115,800 shares, compared to its average volume of 162,820. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.13 and a quick ratio of 6.13. The firm has a fifty day moving average of $3.57 and a two-hundred day moving average of $5.02. Neon Therapeutics has a 1-year low of $2.31 and a 1-year high of $12.69. The company has a market cap of $85.42 million, a P/E ratio of -0.52 and a beta of 1.62.

Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01). Research analysts predict that Neon Therapeutics will post -2.55 EPS for the current fiscal year.



NTGN has been the topic of a number of recent analyst reports. Mizuho set a $21.00 target price on Neon Therapeutics and gave the stock a “buy” rating in a report on Monday, July 1st. Morgan Stanley decreased their target price on Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, July 16th. Zacks Investment Research lowered Neon Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Robert W. Baird initiated coverage on Neon Therapeutics in a report on Thursday, July 25th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, ValuEngine raised Neon Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Neon Therapeutics presently has an average rating of “Buy” and a consensus target price of $14.43.

Large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Neon Therapeutics by 1.1% during the 4th quarter. FMR LLC now owns 2,079,669 shares of the company’s stock valued at $10,461,000 after acquiring an additional 23,075 shares during the period. BlackRock Inc. lifted its position in shares of Neon Therapeutics by 12.0% during the 4th quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock worth $1,548,000 after buying an additional 32,943 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock worth $109,000 after buying an additional 6,493 shares during the last quarter. Northern Trust Corp lifted its position in shares of Neon Therapeutics by 68.9% during the 4th quarter. Northern Trust Corp now owns 88,678 shares of the company’s stock worth $446,000 after buying an additional 36,170 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock worth $98,000 after buying an additional 2,905 shares during the last quarter. Hedge funds and other institutional investors own 69.53% of the company’s stock.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: Death Cross

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.